Clinical Trial Update: Combination Rucaparib With Nivolumab in Small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of rucaparib and nivolumab in small cell lung cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• OPDIVO (nivolumab)
• RUBRACA (RUCAPARIB)

Snippet

Sponsor: Zhonglin Hao | Conditions: Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-12-22